Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX)
Lineage Cell Therapeutics (LCTX) Q2 2026 earnings call: OpRegen, AlloSCOPE/Lineage 3.0 pipeline, cash runway to Q3 2028 & catalystsâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Lineage Cell Therapeutics (LCTX) Q2 2026 earnings call: OpRegen, AlloSCOPE/Lineage 3.0 pipeline, cash runway to Q3 2028 & catalystsâread now.
Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX) | Seeking Alpha
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2026
Management View
"Insights and milestones from the OpRegen program have allowed us to fuel the growth of a new and significantly more internally owned pipeline of cell therapy assets." (CEO, President & Director Brian Culley)
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
What are the main growth drivers for Lineage Cell Therapeutics' internal pipeline?
Growth is being driven by the AlloSCOPE platform, a new internally owned pipeline expansion (Lineage 3.0), development of assets like COR1, ILT1, ReSonance, and a partner-funded OPC1 focus shift.
How does management view progress and risks for OpRegen's advancement?
Management remains confident in OpRegen's progress towards a multicenter trial but notes timelines depend on partners (Roche/Genentech); recent milestones include EMA database registration, GAlette site expansion, but staffing tone is more guarded on details and partner timelines.
What is Lineage Cell Therapeutics' current financial position and operating runway outlook?
As of the call, Lineage has $50.8 million in cash, expecting to fund operations into Q3 2028. This quarter's net income mainly resulted from noncash warrant-liability changes, not cash-generating business activity.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
